Company Announcements

e-therapeutics plc

("e-therapeutics" or the "Company")

Strategic RWE collaboration with Arcturis

London, UK, 02 November 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announces a strategic collaboration with Arcturis Data Limited, a UK data company with a high quality and enriched real-world data platform. The companies will integrate Arcturis' Real-World Evidence (RWE), which utilises a platform comprised of high quality, clinically-rich real-world data, and analytical expertise derived from their unique access to anonymised patient data with e-therapeutics' computational biology platform, HepNet™. The collaboration will focus on delivering novel insights to support innovative therapies for patients with metabolic dysfunction and associated fatty liver disease, including nonalcoholic steatohepatitis (NASH).

Arcturis' RWE outputs will be analysed by e-therapeutics using HepNet™, its proprietary suite of artificial intelligence (AI)-driven algorithms and hepatocyte-centric data sources, to drive the discovery and development of innovative RNAi medicines for the treatment of NASH and related disorders. Under the terms of the agreement, e-therapeutics will have exclusive rights to nominate novel gene targets derived from the collaboration to prosecute genetic medicines using its GalOmic™ RNAi platform.

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented: "This is an important strategic collaboration which enables us to access real-world insights generated from patient data including electronic health records, imaging and biomarker data, and integrate these insights into HepNet™. This effort complements ongoing work at e-therapeutics in metabolic diseases, and we believe that the collaboration will unveil unique insights into the biological mechanisms driving NASH that we can target to deliver effective RNAi medicines to patients."

Alex Snow, Chief Executive Officer of Arcturis, said: "We are delighted to start this collaboration with e-therapeutics. The Arcturis analytics platform derives evidence from anonymised and highly curated longitudinal and granular health data and we are excited to integrate these real-world insights with HepNet™, to deliver powerful findings that may lead to novel and innovative RNAi medicines."

Enquiries:

About Arcturis Data Limited

Arcturis is a real-world data company that works alongside clinical and industry experts to support delivery of research across all phases of the clinical development pipeline, covering all conditions and treatment types. Arcturis are experts in applying both traditional and innovative real-world evidence techniques, covering medical statistics, machine learning, and data science approaches. Arcturis' priority is working with high quality, enriched real-world data that is integrated with important clinical context and built on scientific principles, with the aim of delivering robust outputs for global partners, contributing to improving clinical research, and enhancing patient outcomes. Arcturis is based in Oxfordshire. For more information, visit www.arcturisdata.com.

About e-therapeutics plc

e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic. 

ETX's proprietary HepNet™ platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery. This approach explicitly considers the true complexity of biology to make more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data resource.  The Company generates, prioritises, and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.

GalOmic™, ETX's proprietary RNAi platform, enables targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by HepNet™. The focus on hepatocytes offers the opportunity to tackle a wide variety of diseases.  The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalOmic™ constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.

The Company is progressing a pipeline of first-in-class RNAi candidates across a variety of therapeutic areas with high unmet need, including preclinical programs in cardiometabolic and metabolic diseases, haemophilia, and other undisclosed indications. ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.

The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.